ACC1是脑缺血性卒中潜在的免疫调节靶点
该研究在小鼠短暂性大脑中动脉闭塞模型中,发现脑缺血性卒中上调外周CD4+ T细胞的糖酵解和脂肪酸合成以及ACC1表达。CD4+ T细胞特异性敲除ACC1或热量限制预处理均可减轻缺血性脑损伤并维持调节性T细胞/Th17细胞平衡。药理学抑制ACC1可减轻神经炎症并改善神经功能结局。
要点
- 脑缺血卒中上调CD4+ T细胞ACC1表达及脂肪酸合成。
- CD4+ T细胞敲除ACC1可减轻缺血性脑损伤。
- ACC1抑制剂soraphen A改善卒中后神经功能结局。
核心结论
- ACC1是平衡调节性T细胞与Th17细胞、减轻卒中后神经炎症的新型免疫代谢调节靶点。
研究设计与样本
- 研究采用小鼠短暂性大脑中动脉闭塞60分钟模型。
- 使用CD4 cre与ACC1 fl/fl杂交生成CD4+ T细胞特异性ACC1敲除小鼠。
- 采用Seahorse XF糖酵解 assay和靶向脂质组学检测卒中后CD4+ T细胞代谢变化。
主要发现
- 脑缺血性卒中增加外周CD4+ T细胞糖酵解和脂肪酸合成,并上调ACC1表达。
- 热量限制下调卒中后CD4+ T细胞ACC1表达。
- CD4 creACC1 fl/fl小鼠和热量限制预处理小鼠均显著减少缺血性脑损伤并维持外周调节性T细胞/Th17细胞平衡。
- CD4+ T细胞条件性敲除ACC1减弱了热量限制对缺血性脑损伤和外周调节性T细胞/Th17细胞平衡的保护作用。
- 大脑中动脉闭塞后药理学抑制ACC1减轻神经炎症、维持调节性T细胞/Th17平衡并改善神经功能结局。
临床怎么用
- 抑制ACC1可能成为减轻卒中后神经炎症和改善神经功能结局的免疫代谢调节策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Cerebral ischemic stroke elicits profound responses of CD4+ T cells, which in turn significantly affect the ischemic brain injury. ACC1 (acetyl coenzyme A carboxylase 1) is a key enzyme that has been recently found to propagate CD4+ T cell-associated inflammation by mediating de novo fatty acid synthesis; however, its role in the context of ischemic stroke remains unknown. Methods- Focal cerebral ischemia was induced by transient middle cerebral artery occlusion for 60 minutes in mice. Seahorse XF glycolysis assay and targeted lipidomic profiling were used to detect metabolic changes in CD4+ T cell after stroke. CD4 cre mice were crossed with ACC1 fl/fl mice to generate the CD4+ T-cell-specific deletion of ACC1 (CD4 creACC1 fl/fl mice) mice. Pretreatment with calorie restriction (CR; with 30% reduction of food for 4 weeks before middle cerebral artery occlusion) or post-treatment with ACC1 inhibitor, soraphen A were both used to test the effect of ACC1 modulation on poststroke neuroinflammation. Results- Cerebral ischemic stroke increased glycolysis and fatty acid synthesis in peripheral CD4+ T cells, in which the expression of ACC1 was also upregulated. CR downregulated the expression of ACC1 in CD4+ T cells after stroke. Both CD4 creACC1 fl/fl mice and CR-pretreated mice exhibited significantly reduced ischemic brain injury and preserved the balance of peripheral regulatory T cells/T helper 17 (Th17) cells. Furthermore, conditional knockout of ACC1 in CD4+ T cells attenuated the protection exerted by CR both on ischemic brain injury and peripheral balance of regulatory T cells/Th17 cells. Pharmacological inhibition of ACC1 after middle cerebral artery occlusion attenuates neuroinflammation, preserves regulatory T cells/Th17 balance, and improves neurological outcomes after ischemic stroke. Conclusions- ACC1 is a novel immune metabolic modulation target to balance the regulatory T cells and Th17 cells and blunt neuroinflammation after stroke. Inhibition of ACC1 can be a previously unrecognized mechanism that underlies CR-afforded neuroprotection against cerebral ischemic stroke.
引用
- Wang X, Zhou Y, Tang D, et al. ACC1 (Acetyl Coenzyme A Carboxylase 1) Is a Potential Immune Modulatory Target of Cerebral Ischemic Stroke. Stroke. 2019. PMID: 31177975. doi:10.1161/STROKEAHA.119.024564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。